New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib

@inproceedings{Richardson2017NewDI,
  title={New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib},
  author={Paul G Richardson and Shaji K Kumar and Jacob P Laubach and Claudia E Paba-Prada and Neeraj Gupta and Deborah T Berg and Helgi J K van de Velde and Philippe Moreau},
  booktitle={Journal of blood medicine},
  year={2017}
}
Ixazomib is the first oral proteasome inhibitor to be approved, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was on the basis of results from the phase 3, double-blind, placebo-controlled TOURMALINE-MM1 study, which demonstrated a 35… CONTINUE READING